Pharmacoepidemiology and Drug Safety

Papers
(The H4-Index of Pharmacoepidemiology and Drug Safety is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Accuracy of Japanese claims data in identifying diabetes‐related complications56
Control yourself: ISPE‐endorsed guidance in the application of self‐controlled study designs in pharmacoepidemiology40
Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators37
Validation of diagnosis codes to identify hospitalized COVID‐19 patients in health care claims data34
QTc prolongation in COVID‐19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta‐analysis30
Core concepts in pharmacoepidemiology: Violations of the positivity assumption in the causal analysis of observational data: Consequences and statistical approaches28
HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force27
Safety of Andrographis paniculata: A systematic review and meta‐analysis24
Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data23
Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis23
Comparison of drug prescribing before and during the COVID‐19 pandemic: A cross‐national European study23
Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID‐19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 322
Core concepts in pharmacoepidemiology: Validation of health outcomes of interest within real‐world healthcare databases22
Real‐world evidence to support regulatory decision making: New or expanded medical product indications21
Polypharmacy and the risk of drug–drug interactions and potentially inappropriate medications in hospital psychiatry21
A COVID‐19‐ready public health surveillance system: The Food and Drug Administration's Sentinel System20
Antidepressant use in Australia and Sweden—A cross‐country comparison19
Validity of claims‐based algorithms for selected cancers in Japan: Results from the VALIDATE‐J study19
Utilization of drugs with reports on potential efficacy or harm on COVID‐19 before, during, and after the first pandemic wave18
Bipolar disorder prevalence and psychotropic medication utilisation in Hong Kong and the United Kingdom18
High‐dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reporting18
0.054095029830933